TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1797191

Group type: EXPERIMENTAL
Intervention: 773U82.HCl at doses ranging from 15 mg/m2 to 980 mg/m2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 773U82.HCl at 980 mg/m2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 773U82.HCl at 720 mg/m2
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 773U82.HCl infusion duration increase
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 773U82.HCl
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 773U82.HCl pharmacokinetic studies
Number of subjects: 36
Study: 6679239

Group type: EXPERIMENTAL
Intervention: Combination of cost education and cost audits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faculty chart review
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30600265

Group type: EXPERIMENTAL
Intervention: Genomic Sequencing (GS)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Newborn Screening (NBS)
Number of subjects: 493
Study: 30669797

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (2 ml normal saline)
Number of subjects: 81
Study: 26012474

Group type: EXPERIMENTAL
Intervention: Nicorandil administration after primary PCI
Number of subjects: 32
Study: 23719148

Group type: EXPERIMENTAL
Intervention: Quality Improvement Tool - Pocket reminder card with preventive medication guidelines
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Quality Improvement Tool - Monthly team feedback reports
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Quality Improvement Tool - Refrigerator magnet patient reminder card
Number of subjects: 213

Group type: COMPARATOR
Intervention: Baseline comparison group (no intervention)
Number of subjects: 213
Study: 20499312

Group type: EXPERIMENTAL
Intervention: Model I (tumours with potential for progression)
Number of subjects: 2310

Group type: EXPERIMENTAL
Intervention: Model II (tumours without potential for progression)
Number of subjects: 2310

Group type: EXPERIMENTAL
Intervention: Observed prevalence from ERSPC-Rotterdam
Number of subjects: 2310

Group type: COMPARATOR
Intervention: ERSPC-Rotterdam data
Number of subjects: 2310
Study: 19141764

Group type: COMPARATOR
Intervention: Supervised treadmill exercise
Number of subjects: 156

Group type: COMPARATOR
Intervention: Lower extremity resistance training
Number of subjects: 156
Study: 17424755

Group type: EXPERIMENTAL
Intervention: Earlier cessation of desflurane supply
Number of subjects: 30

Group type: COMPARATOR
Intervention: Desflurane supply continued until the end of the operation
Number of subjects: 30
Study: 15383254

Group type: EXPERIMENTAL
Intervention: Herbal formula of TongxieYaofang and clostridium butyricum (Cb) for four weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clostridium butyricum (Cb) for four weeks
Number of subjects: 60
Study: 11485888

Group type: EXPERIMENTAL
Intervention: gentamicin + clindamycin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: tobramycin + clindamycin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: meropenem
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: imipenem
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: aztreonam + clindamycin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: cefoxitin
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: cefotetan
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: moxalactam
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: cefotaxime + metronidazole
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: piperacillin/tazobactam
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: ticarcillin/clavulanic acid
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: quinolone studies
Number of subjects: 79
Study: 9699364

Group type: EXPERIMENTAL
Intervention: Trials published in English
Number of subjects: 229

Group type: COMPARATOR
Intervention: Trials published in other languages (French, German, Italian, Spanish)
Number of subjects: 229
Study: 8626882

Group type: EXPERIMENTAL
Intervention: 240 mg COER-verapamil at 8:00 AM on an empty stomach, subjects remaining ambulatory
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 240 mg COER-verapamil at 8:00 AM on an empty stomach, subjects remaining supine for 8 hours
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 240 mg COER-verapamil at 10:00 PM with a standardized meal, subjects remaining supine for 8 hours
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 240 mg COER-verapamil at 10:00 PM on an empty stomach, subjects remaining supine for 8 hours
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Time of dosing
Number of subjects: 29
Study: 1972124

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 75 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 150 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 300 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: roxatidine acetate 600 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: roxatidine acetate (all dosages)
Number of subjects: 10
Study: 352976

Group type: EXPERIMENTAL
Intervention: Chlorpromazine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study: 31346900

Group type: EXPERIMENTAL
Intervention: Tuncali et al. formula
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hong‐yun Liu et al. formula
Number of subjects: 80
Study: 31590989

Group type: EXPERIMENTAL
Intervention: Community-initiated kangaroo mother care
Number of subjects: 8402

Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 8402
Study: 26350524

Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Both WBI and APBI
Number of subjects: 117
Study: 23376852

Group type: EXPERIMENTAL
Intervention: Acupuncture (group I)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No adjunctive treatment (control group II)
Number of subjects: 62
Study: 21757334

Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Number of subjects: 127

Group type: COMPARATOR
Intervention: Docetaxel plus placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Bevacizumab (both doses)
Number of subjects: 127
Study: 19968384

Group type: EXPERIMENTAL
Intervention: CT + pharmacotherapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 42
Study: 16364575

Group type: EXPERIMENTAL
Intervention: Two doses of trimegestone (TMG)
Number of subjects: 487

Group type: COMPARATOR
Intervention: Norethisterone acetate (NETA)
Number of subjects: 487
Study: 15365734

Group type: EXPERIMENTAL
Intervention: roxithromycin 300 mg/OD for 6 weeks
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 10751747

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bezafibrate 400 mg
Number of subjects: 45
Study: 9365041

Group type: EXPERIMENTAL
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Ultrasound angiography with intraarterial CO2 microbubbles (USAG)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Computed tomography during arterial portography (CTAP)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Immunohistochemistry using QB monoclonal antibody
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Angiographic findings
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Decrease in portal perfusion
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Hepatocellular carcinomas with fatty metamorphosis
Number of subjects: 35
Study: 1562863

Group type: EXPERIMENTAL
Intervention: 10, 20 or 30 mg/day of oral fluphenazine hydrochloride
Number of subjects: 41
Study: 3909333

Group type: EXPERIMENTAL
Intervention: Aztreonam plus tobramycin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Aztreonam plus cloxacillin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Moxalactam plus tobramycin
Number of subjects: 45
Study: 31430616

Group type: EXPERIMENTAL
Intervention: Visceral osteopathic technique
Number of subjects: 94

Group type: COMPARATOR
Intervention: Superficial manipulation (placebo)
Number of subjects: 94
Study: 29897866

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with extra-virgin olive oil
Number of subjects: 7447

Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with mixed nuts
Number of subjects: 7447

Group type: COMPARATOR
Intervention: Control diet (advice to reduce dietary fat)
Number of subjects: 7447
Study: 26768569

Group type: COMPARATOR
Intervention: Various treatment alternatives for Ebola virus, including repurposed drugs; specific dosages and durations not mentioned.
Number of subjects: 0
Study: 25200552

Group type: EXPERIMENTAL
Intervention: Loading dose of vitamin D3 (250,000 IU) followed by oral maintenance vitamin D3/calcium (800 IU/500 mg)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 22451449

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lesser coronary plaque regression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Greater coronary plaque regression
Number of subjects: 0
Study: 21162726

Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stabilization Exercise (SE)
Number of subjects: 100
Study: 17329285

Group type: EXPERIMENTAL
Intervention: Supervised group exercise
Number of subjects: 32

Group type: COMPARATOR
Intervention: Unsupervised home exercise
Number of subjects: 32
Study: 15642910

Group type: EXPERIMENTAL
Intervention: AN1792 (50 or 225 microg) with QS‐21 adjuvant (50 or 100 microg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: AN1792 + QS‐21
Number of subjects: 80

Group type: COMPARATOR
Intervention: QS‐21 only (control)
Number of subjects: 80
Study: 11907497

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 403

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 403
Study: 9800141

Group type: EXPERIMENTAL
Intervention: Ethanol (0.25 g/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (30% N2O in oxygen)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ethanol and Nitrous oxide (combination)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (100% oxygen)
Number of subjects: 11
Study: 8777409

Group type: EXPERIMENTAL
Intervention: Intracavernous injection of 10 mg moxisylyte
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 2178693

Group type: EXPERIMENTAL
Intervention: Arecoline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6107678

Group type: EXPERIMENTAL
Intervention: 13‐cis retinoic acid (0.1 mg‐1.0 mg/kg body‐weight)
Number of subjects: 0
Study: 31304536

Group type: EXPERIMENTAL
Intervention: Ibrexafungerp 750 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ibrexafungerp 500 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Fluconazole (SOC)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Micafungin (continued therapy)
Number of subjects: 27
Study: 27845219

Group type: EXPERIMENTAL
Intervention: Daily low-dose tadalafil (5 mg)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 25877748

Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy after gefitinib
Number of subjects: 71
Study: 24219098

Group type: EXPERIMENTAL
Intervention: 30% lavender oil
Number of subjects: 64

Group type: COMPARATOR
Intervention: Inactive control oil
Number of subjects: 64
Study: 21219593

Group type: EXPERIMENTAL
Intervention: Cell phone-supported cognitive behavioural therapy (CBT) for anxiety disorders; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 19203298

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 50 mg
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 75 mg
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Tapentadol IR 100 mg
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Oxycodone HCl IR 15 mg
Number of subjects: 603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study: 17893579

Group type: EXPERIMENTAL
Intervention: Lighter general anesthesia (propofol 2 mug/mL and rimifentanil 2 ng/mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (propofol 4 microg/mL and rimifentanil 4 ng/mL)
Number of subjects: 50
Study: 15591955

Group type: EXPERIMENTAL
Intervention: Short-term cyclosporine followed by azathioprine and prednisolone (CyAP)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Long-term cyclosporine alone (Cy)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Azathioprine and prednisolone alone (AP)
Number of subjects: 489
Study: 11419519

Group type: EXPERIMENTAL
Intervention: Educational intervention alone
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: Educational intervention in the presence of a significant other
Number of subjects: 646

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 646
Study: 15321210

Group type: EXPERIMENTAL
Intervention: Bupivacaine 9.375 mg (15 ml of 0.0625%) with fentanyl 37.5 microg and adrenaline 37.5 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg (15 ml of 0.1%) with fentanyl 30 microg and adrenaline 30 microg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine 10 mg (4 ml of 0.25% ‐ test) followed by bupivacaine 20 mg (8 ml of 0.25% ‐ loading)
Number of subjects: 0
Study: 7943835

Group type: EXPERIMENTAL
Intervention: Desflurane at 8% (1.1 MAC) for 10 min after an initial increase from 4%
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Subsequent increases in desflurane concentration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ulnar nerve stimulation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Desflurane with 60% nitrous oxide
Number of subjects: 9
Study: 3508193

Group type: EXPERIMENTAL
Intervention: Nippon Colin BP-103N blood pressure monitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hawksley random zero mercury sphygmomanometer
Number of subjects: 0
Study: 29266092

Group type: EXPERIMENTAL
Intervention: FEDWASH (30 g CHO·h during SS + WASH during TT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: FEDPLA (30 g CHO·h during SS + placebo wash during TT)
Number of subjects: 10
Study: 28419170

Group type: EXPERIMENTAL
Intervention: Couple-based cognitive behaviour therapy (CBT)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: One-to-one cognitive behaviour therapy (CBT)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 83
Study: 25185593

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Acetate-buffered balanced crystalloid
Number of subjects: 150
Study: 23974823

Group type: EXPERIMENTAL
Intervention: Concomitant TMZ (75 mg/m²/day) during the first and last weeks of RT in the RT-TMZ-10.00 study
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Concomitant TMZ (75 mg/m²/day) during all weeks of RT in the RT-TMZ-01.04 trial
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Adjuvant TMZ (200 mg/m²) administered for 5 days every 28 days
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard treatment regimens (implied control)
Number of subjects: 104
Study: 20670755

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 427

Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 427
Study: 19092151

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1050
Study: 15990745

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CrPic) 1000 microg daily for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for the first 3 months, then CrPic for the next 3 months
Number of subjects: 60
Study: 12848714

Group type: EXPERIMENTAL
Intervention: Tooth gingival transplantation (TGT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional method (tooth with periodontal ligament)
Number of subjects: 76
Study: 10778590

Group type: EXPERIMENTAL
Intervention: Tegretol 200
Number of subjects: 12

Group type: COMPARATOR
Intervention: Zen‐200
Number of subjects: 12
Study: 8720373

Group type: EXPERIMENTAL
Intervention: Fish oil (1.8 g of n-3 PUFA)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 37
Study: 2036564

Group type: EXPERIMENTAL
Intervention: Omnipaque 350
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Niopam 370
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omnipaque 300
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Niopam 300
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultravist 300
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diluted media (150 mgI/ml)
Number of subjects: 0

Group type: COMPARATOR
Intervention: All 300 strength contrast media diluted to 150 strength
Number of subjects: 0
Study: 7055525

Group type: EXPERIMENTAL
Intervention: Extradural morphine (4mg before skin incision and an additional 4mg at skin closure)
Number of subjects: 36

Group type: COMPARATOR
Intervention: General anaesthesia (halothane) plus systemic opiates
Number of subjects: 36

Group type: COMPARATOR
Intervention: Continuous extradural analgesia with bupivacaine
Number of subjects: 36
Study: 31734419

Group type: EXPERIMENTAL
Intervention: Sevoflurane postconditioning (1 minimum alveolar concentration for 15 minutes after reperfusion)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Sevoflurane postconditioning
Number of subjects: 152
Study: 31648461

Group type: EXPERIMENTAL
Intervention: SRI=100% group
Number of subjects: 1829

Group type: COMPARATOR
Intervention: 50%≤SRI<100% group
Number of subjects: 1829

Group type: COMPARATOR
Intervention: SRI<50% group
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: SRI<65%
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: SRI=65%
Number of subjects: 1829
Study: 28533226

Group type: EXPERIMENTAL
Intervention: Chemotherapy with concurrent trastuzumab (Arm C)
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Chemotherapy alone (Arm A)
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Chemotherapy with sequential trastuzumab (Arm B)
Number of subjects: 1734
Study: 25643353

Group type: EXPERIMENTAL
Intervention: Low-iodine group (270 mg I/mL, 100 kVp) with iterative reconstruction (IR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: High-iodine group (370 mg I/mL, 120 kVp)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-iodine group
Number of subjects: 100
Study: 22987136

Group type: EXPERIMENTAL
Intervention: Amiodarone (group A; 219 patients) - intravenous infusion (15 mg/kg for 48 h postoperatively) after a loading dose (5 mg/kg)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (group M; 219 patients) - loading dose (80 mg/kg over 30 min preoperatively) and then intravenous infusion (8 mg/kg/h for 48 h)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Control group (group C; 219 patients) - analyzed retrospectively
Number of subjects: 438
Study: 21316089

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided puncture PCNL
Number of subjects: 131

Group type: COMPARATOR
Intervention: Doppler ultrasound-guided PCNL
Number of subjects: 131
Study: 19635156

Group type: EXPERIMENTAL
Intervention: Belatacept (n = 4)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Cyclosporine (n = 3)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Belatacept and Cyclosporine
Number of subjects: 7
Study: 17523328

Group type: EXPERIMENTAL
Intervention: Synbiotic 2000 (lactobacilli preparations with 10^10 CFU and prebiotics)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Synbiotic 2000
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (only prebiotics)
Number of subjects: 62
Study: 15466687

Group type: EXPERIMENTAL
Intervention: RCTs presented at the Society for Pediatric Research meetings
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Unpublished RCTs
Number of subjects: 393
Study: 11495873

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg po
Number of subjects: 200

Group type: COMPARATOR
Intervention: Diazepam 10 mg po
Number of subjects: 200
Study: 9706735

Group type: EXPERIMENTAL
Intervention: Topiramate (doses not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate (high doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate (doses beyond 600 mg/day)
Number of subjects: 0
Study: 7817799

Group type: EXPERIMENTAL
Intervention: Sodium fluoride treatment (60 mg NaF/day for 1-2 years)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 7

Group type: COMPARATOR
Intervention: Osteoporotic bone before fluoride treatment
Number of subjects: 7
Study: 3287971

Group type: EXPERIMENTAL
Intervention: cefotetan
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: moxalactam
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: cefoxitin
Number of subjects: 303
Study: 30969209

Group type: EXPERIMENTAL
Intervention: Backfill-assisted void trial (group A)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Spontaneous voiding trial (group B)
Number of subjects: 153
Study: 29339649

Group type: EXPERIMENTAL
Intervention: High monounsaturated fatty acids (MUFAs) hypocaloric diet (diet M)
Number of subjects: 361

Group type: COMPARATOR
Intervention: High polyunsaturated fatty acids (PUFAs) hypocaloric diet (diet P)
Number of subjects: 361
Study: 25710303

Group type: EXPERIMENTAL
Intervention: New credo aftercare program (12 months duration) for rehabilitation patients with relevant impairments.
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: New credo aftercare program (12 months duration) for rehabilitation patients with low impairments.
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group without aftercare program.
Number of subjects: 238
Study: 24364538

Group type: EXPERIMENTAL
Intervention: Intranasal users
Number of subjects: 412

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 412